Competing Interests
Dr. Nierenberg has served as a consultant for Abbott Laboratories, Alkermes, American Psychiatric Association, Appliance Computing (MindSite), Basliea, Brain Cells, Brandeis University, Bristol-Myers Squibb, Celexio, Clintara, Corcept, Dainippon Sumitomo (now Sunovion Pharmaceuticals), Dey Pharmaceuticals, Eli Lilly, EpiQ, Forest, Genaissance, Genentech, GlaxoSmithKline, Healthcare Global Village, Hoffman LaRoche, Infomedic, Intra-Cellular Therapies, Janssen Pharmaceutica, Jazz Pharmaceuticals, L.P./Mylan, Lundbeck, MedAvante, Merck, MSI Methylation Sciences, Naurex, Neurocrine, Neuronetics, NeuroRx, Novartis, Otsuka, Pamlab, Parexel, Pfizer, PGx Health, Ridge Diagnostics, Sage Pharmaceuticals, Schering-Plough, Shire, Somerset, Sunovion Pharmaceuticals, Supernus, Takeda Pharmaceuticals, Targacept, and Teva, and he has also served as a consultant through the MGH Clinical Trials Network and Institute (CTNI) for Assurex, AstraZeneca, BrainCells, Dainippon Sumitomo/Sepracor, Johnson & Johnson, LaboPharm, Merck, MSI Methylation Sciences, NeuroRx Pharma, Novartis, Pfizer, PGx Health, Physician’s Postgraduate Press, Schering-Plough, Shire, Takeda/Lundbeck, and Targacept; he has received honoraria from American Drug Utilization Review, American Professional Society of ADHD and Related Disorders, American Society of Clinical Psychopharmacology, Baystate Medical Center, Belvoir Publishing, Brandeis University, Bristol-Myers Squibb, CME Institute, Columbia University, Congress of the Hellenic Society for Basic and Clinical Pharmacology, CRICO, Dartmouth Medical School, Guilford Publications, Harold Grinspoon Charitable Foundation, Health New England, Hillside Hospital, IMEDEX, Institute of Medicine, International Society for Bipolar Disorders, International Society for CNS Clinical Trials and Methodology, Israel Society for Biological Psychiatry, Johns Hopkins University, MBL Publishing, Medscape, MGH Psychiatry Academy, MJ Consulting, NAMI, National Association of Continuing Education, National Network of Depression Centers, New Clinical Drug Evaluation Unit, New York State, Nova Southeastern University, Physicians Postgraduate Press, Psychiatric Annals, Rush Medical College, SciMed, Slack Publishing, SUNY Buffalo, University of Miami, University of Michigan, University of Pisa, University of Texas Southwestern Dallas, University of Wisconsin at Madison, UpToDate, Wiley Publications, Wolters Kluwer Publishing, World Congress on Brain Behavior and Emotion, and Yale University School of Medicine; he has served on advisory boards of Appliance Computing, Brain Cells, Eli Lilly, Genentech, InfoMedic, Johnson & Johnson, Takeda/Lundbeck Pharmaceuticals, and Targacept; he owns stock options in Appliance Computing (MindSite), Brain Cells, and MedAvante; and he has copyrights on the Clinical Positive Affect Scale and the MGH Structured Clinical Interview for the Montgomery-Åsberg Depression Rating Scale exclusively licensed to the MGH Clinical Trials Network and Institute. Dr. Wilkinson has received contract funding from Janssen and Sage Therapeutics for the conduct of clinical trials administered through Yale University, and he anticipates receiving contract funding from LivaNova for conducting clinical trials; he has received consulting fees from Biohaven Pharmaceuticals, Janssen, and Oui Therapeutics. The other authors report no financial relationships with commercial interests.